Validated Benefits

MicronJetTM has demonstrated significant dose sparing with various vaccines with down to 4% of the original dose1-8,10. It is also the first intradermal device to demonstrate dose sparing in pandemic flu4.
MicronJetTM has demonstrated a superior immune response to full dose Fluzone® intramuscular5 and improved immunogenicity to full-dose ZostaVax® and overall trend for superiority with lower doses8.